MAX
Calendrier AdvisorShares Psychedelics ETF
Calendrier simple
Calendrier prolongé
Les principaux paramètres
| 10 rentabilité d'été | 0 |
| 3 rentabilité d'été | 32.79 |
| 5 rentabilité d'été | 0 |
| Bêta | 0.4 |
| Commission | 0.99 |
| Devise | usd |
| ISIN CODE | US00768Y3624 |
| Indice | ACTIVE - No Index |
| La date de la base | 2021-09-15 |
| Le nombre d'entreprises | 13 |
| P / BV moyen | 1.75 |
| P / E moyen | 9.46 |
| P / S moyen | 2.15 |
| Pays | USA |
| Pays ISO | US |
| Propriétaire | AdvisorShares |
| Rentabilité annuelle | 20.42 |
| Rentabilité divine | 0.31 |
| Région | Global |
| Site web | Système |
| Top 10 des émetteurs,% | 57.12 |
| Type d'actif | Equity |
| Changement dans la journée | 0% 17.028 $ |
| Changement de la semaine | -1.6% 17.305 $ |
| Changement en un mois | -0.83% 17.17 $ |
| Changement en 3 mois | -8.5% 18.61 $ |
| Changement en six mois | -16.42% 20.373 $ |
| Changement pour l'année | +20.42% 14.14 $ |
| Changement depuis le début de l'année | -1.29% 17.25 $ |
Payer l'abonnement
Plus de fonctionnalités et de données pour l'analyse des entreprises et du portefeuille sont disponibles par abonnement
Meilleures entreprises
| Nom | Industrie | Partager, % | P/BV | P/S | P/E | EV/Ebitda | Rendement des dividendes | |
| #1 |
 COMPASS Pathways plc |
Healthcare | 7.8644 | 1.65 | 0 | -1.91 | -0.69 | 0 |
| #2 |
 Alkermes plc |
Healthcare | 7.7698 | 3.32 | 3.13 | 13.27 | 9.4 | 0 |
| #3 |
 Relmada Therapeutics, Inc. |
Healthcare | 6.6722 | 0.39 | 0 | -0.21 | -0.12 | 0 |
| #4 |
 GH Research PLC |
Healthcare | 6.1726 | 2.04 | 0 | -17.08 | -6.96 | 0 |
| #5 |
 Neurocrine Biosciences |
Healthcare | 5.8272 | 5.49 | 6.03 | 41.64 | 22.57 | 0 |
| #6 |
 Supernus Pharmaceuticals, Inc. |
Healthcare | 5.2346 | 1.99 | 3.12 | 27.96 | 11.39 | 0 |
| #7 |
 Alto Neuroscience, Inc. |
Healthcare | 5.0798 | 1.93 | 0 | -1.26 | -2.06 | 0 |
| #8 |
 AbbVie |
Healthcare | 4.6133 | 92.87 | 6.64 | 96.15 | 25.13 | 2.97 |
| #9 |
 Johnson & Johnson |
Healthcare | 4.3527 | 4.83 | 3.88 | 24.53 | 14.43 | 2.79 |
| #10 |
 NRx Pharmaceuticals, Inc. |
Healthcare | 3.5295 | -0.69 | 0 | -1.21 | -1.15 | 0 |
Similaire ETF
Autres ETF de la société de gestion
| Nom | Classe | Catégorie | Commission | Rentabilité annuelle |
| Equity | 0.83 | 61.39 | ||
| Equity | 0.84 | -0.91 | ||
| Equity | 1.18 | 8.94 | ||
| Equity | 0.95 | -5.36 | ||
| Equity | 1.28 | 23.28 | ||
| Multi-Asset | 1.71 | 11.95 | ||
| Equity | 1.03 | 50.52 | ||
| Equity | 0.9 | 14.31 | ||
| Equity | 1.1 | 21.77 | ||
| Multi-Asset | 1.51 | 21.53 | ||
| Equity | 0.75 | 11.26 | ||
| Equity | 2.84 | -17.15 | ||
| Equity | 1 | 7.68 | ||
| Equity | 1.01 | -9.01 | ||
| Equity | 0.99 | 1.65 |
Description AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Basé sur des sources: porti.ru
